Search results (31)
« Back to PublicationsSystemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunity.
Steffke EE. et al, (2026), bioRxiv
Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF.
Ma B. et al, (2026), Science immunology, 11
Unlocking cancer vaccine potential: What are the key factors?
Grant M. et al, (2024), Human vaccines & immunotherapeutics, 20
Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.
McAuliffe J. et al, (2024), Journal for immunotherapy of cancer, 12
Genomic Landscape of Epstein-Barr Virus in Endemic Burkitt Lymphoma
Legason ID. et al, (2023), Blood, 142, 2985 - 2985
Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.
Ramirez-Valdez RA. et al, (2023), Cell reports, 42
Heterologous prime-boost viral vector cancer vaccines have protective effects against a syngeneic mouse model of glioblastoma
Steffke EE. et al, (2023), JOURNAL OF IMMUNOLOGY, 210
Heterologous primeboost viral vector vaccines for the treatment of a P1A-expressing BGL1 glioblastoma model
Steffke EE. et al, (2023), CANCER RESEARCH, 83
Human ZBP1 induces cell death-independent inflammatory signaling via RIPK3 and RIPK1.
Peng R. et al, (2022), EMBO reports, 23
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.
Leung CSK. and Van den Eynde BJ., (2022), Cancer cell, 40, 903 - 905
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J. et al, (2021), Journal for immunotherapy of cancer, 9
Vaccination against the Epstein-Barr virus.
Rühl J. et al, (2020), Cellular and molecular life sciences : CMLS, 77, 4315 - 4324
Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.
Rühl J. et al, (2019), The Journal of clinical investigation, 129, 2071 - 2087